Moreover, in an exploratory study, both sPDL1 and sCTLA4 were correlated with poor outcome in patients with metastatic renal clear cell carcinoma treated with tyrosine kinase inhibitors (TKI) [23]. Here, SPDL1 is linked to clear cell renal carcinoma.